LU85344A1 - N-oxydes d'esters d'acide pyridyl carboxylique,leur preparation et leur utilisation - Google Patents
N-oxydes d'esters d'acide pyridyl carboxylique,leur preparation et leur utilisation Download PDFInfo
- Publication number
- LU85344A1 LU85344A1 LU85344A LU85344A LU85344A1 LU 85344 A1 LU85344 A1 LU 85344A1 LU 85344 A LU85344 A LU 85344A LU 85344 A LU85344 A LU 85344A LU 85344 A1 LU85344 A1 LU 85344A1
- Authority
- LU
- Luxembourg
- Prior art keywords
- compound according
- oxide
- group
- hyperlipidemia
- carboxylic acid
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 11
- 150000001733 carboxylic acid esters Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 38
- -1 Pyridyl carboxylic acid ester N-oxide Chemical class 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 10
- 150000001204 N-oxides Chemical class 0.000 claims description 9
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 229960000583 acetic acid Drugs 0.000 claims description 3
- 230000001315 anti-hyperlipaemic effect Effects 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000012362 glacial acetic acid Substances 0.000 claims description 3
- 150000004965 peroxy acids Chemical class 0.000 claims description 3
- IGZUQUCLEJITAB-UHFFFAOYSA-N 2-(2-cyclohexylphenyl)-1-oxidopyridin-1-ium-3-carboxylic acid Chemical compound OC(=O)C1=CC=C[N+]([O-])=C1C1=CC=CC=C1C1CCCCC1 IGZUQUCLEJITAB-UHFFFAOYSA-N 0.000 claims description 2
- DESCEKJWVVRAQC-UHFFFAOYSA-N 2-(4-cyclohexylphenyl)-1-oxidopyridin-1-ium-3-carboxylic acid Chemical compound OC(=O)C1=CC=C[N+]([O-])=C1C1=CC=C(C2CCCCC2)C=C1 DESCEKJWVVRAQC-UHFFFAOYSA-N 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- OUZWJTGVKVJSFA-UHFFFAOYSA-N 2-(2-tert-butyl-4-cyclohexylphenyl)-1-oxidopyridin-1-ium-3-carboxylic acid Chemical compound CC(C)(C)C1=CC(C2CCCCC2)=CC=C1C1=C(C(O)=O)C=CC=[N+]1[O-] OUZWJTGVKVJSFA-UHFFFAOYSA-N 0.000 claims 1
- NEVGJMMPTJKDJA-UHFFFAOYSA-N 6-cyclohexyl-1-oxido-2-phenylpyridin-1-ium-3-carboxylic acid Chemical compound C1CCC(CC1)C2=[N+](C(=C(C=C2)C(=O)O)C3=CC=CC=C3)[O-] NEVGJMMPTJKDJA-UHFFFAOYSA-N 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 27
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 235000001968 nicotinic acid Nutrition 0.000 description 11
- 239000011664 nicotinic acid Substances 0.000 description 10
- 229960003512 nicotinic acid Drugs 0.000 description 8
- 150000002632 lipids Chemical class 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 150000003626 triacylglycerols Chemical class 0.000 description 7
- 201000001320 Atherosclerosis Diseases 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 108090001030 Lipoproteins Proteins 0.000 description 4
- 102000004895 Lipoproteins Human genes 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 235000021588 free fatty acids Nutrition 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000002824 peroxisome Anatomy 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003524 antilipemic agent Substances 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000000923 atherogenic effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229960001214 clofibrate Drugs 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 235000015108 pies Nutrition 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- KSTIXPJVWUSZJG-UHFFFAOYSA-N 1-oxido-2-phenylpyridin-1-ium-3-carboxylic acid Chemical compound C1=CC=C(C=C1)C2=C(C=CC=[N+]2[O-])C(=O)O KSTIXPJVWUSZJG-UHFFFAOYSA-N 0.000 description 1
- KJHYAEZMOHLVCH-UHFFFAOYSA-N 2-ethyl-1-benzofuran Chemical compound C1=CC=C2OC(CC)=CC2=C1 KJHYAEZMOHLVCH-UHFFFAOYSA-N 0.000 description 1
- YNJSNEKCXVFDKW-UHFFFAOYSA-N 3-(5-amino-1h-indol-3-yl)-2-azaniumylpropanoate Chemical compound C1=C(N)C=C2C(CC(N)C(O)=O)=CNC2=C1 YNJSNEKCXVFDKW-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- MVQVNTPHUGQQHK-UHFFFAOYSA-N 3-pyridinemethanol Chemical compound OCC1=CC=CN=C1 MVQVNTPHUGQQHK-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 241001137251 Corvidae Species 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 241000042032 Petrocephalus catostoma Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000006053 animal diet Substances 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 230000036523 atherogenesis Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- 229960003545 benzarone Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- TXCGAZHTZHNUAI-UHFFFAOYSA-N clofibric acid Chemical compound OC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 TXCGAZHTZHNUAI-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002771 effect on peroxisome Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000000260 hypercholesteremic effect Effects 0.000 description 1
- 230000000999 hypotriglyceridemic effect Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 150000002814 niacins Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- XCRBXWCUXJNEFX-UHFFFAOYSA-N peroxybenzoic acid Chemical class OOC(=O)C1=CC=CC=C1 XCRBXWCUXJNEFX-UHFFFAOYSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001855 preneoplastic effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- KNBZBXCCUDRUIK-UHFFFAOYSA-N pyridine-3-carboxylic acid;dihydrochloride Chemical compound Cl.Cl.OC(=O)C1=CC=CN=C1 KNBZBXCCUDRUIK-UHFFFAOYSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000002666 vasoprotective effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19833315877 DE3315877A1 (de) | 1983-05-02 | 1983-05-02 | N-oxide von pyridyl-carbonsaeureestern, ein verfahren zu ihrer herstellung und pharmazeutische mittel, die diese verbindungen enthalten |
| DE3315877 | 1983-05-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LU85344A1 true LU85344A1 (fr) | 1986-01-29 |
Family
ID=6197884
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU85344A LU85344A1 (fr) | 1983-05-02 | 1984-05-02 | N-oxydes d'esters d'acide pyridyl carboxylique,leur preparation et leur utilisation |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US4758581A (de) |
| JP (1) | JPS59206357A (de) |
| KR (1) | KR860001907B1 (de) |
| AU (1) | AU564780B2 (de) |
| BE (1) | BE899558A (de) |
| CA (1) | CA1247092A (de) |
| CH (1) | CH660005A5 (de) |
| CS (1) | CS241082B2 (de) |
| DE (1) | DE3315877A1 (de) |
| DK (1) | DK159105C (de) |
| ES (1) | ES532079A0 (de) |
| FI (1) | FI80444C (de) |
| FR (1) | FR2545486B1 (de) |
| GB (1) | GB2139621B (de) |
| GR (1) | GR79862B (de) |
| HU (1) | HU191681B (de) |
| IE (1) | IE57393B1 (de) |
| IL (1) | IL71734A (de) |
| IT (1) | IT1206144B (de) |
| LU (1) | LU85344A1 (de) |
| NL (1) | NL8401357A (de) |
| SE (1) | SE454986B (de) |
| YU (1) | YU45900B (de) |
| ZA (1) | ZA843278B (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6746691B2 (en) | 1993-09-20 | 2004-06-08 | Kos Pharmaceuticals, Inc. | Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics |
| US6080428A (en) | 1993-09-20 | 2000-06-27 | Bova; David J. | Nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
| US6129930A (en) | 1993-09-20 | 2000-10-10 | Bova; David J. | Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night |
| US6676967B1 (en) | 1993-09-20 | 2004-01-13 | Kos Pharmaceuticals, Inc. | Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia |
| US6818229B1 (en) | 1993-09-20 | 2004-11-16 | Kos Pharmaceuticals, Inc. | Intermediate release nicotinic acid compositions for treating hyperlipidemia |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1256M (fr) * | 1961-06-26 | 1962-04-16 | M I P Soc Amilloise De Prod Ch | Médicament hypocholésterolémiant a base de n-oxyde de l'acide nicotinique. |
| GB1213162A (en) * | 1966-11-16 | 1970-11-18 | Astra Ab | Serum lipid lowering pyridine derivatives and their preparation |
| AT291853B (de) * | 1967-03-22 | 1971-08-10 | Buero Patent Ag | Automatische, gleislose Förderanlage |
| US4321268A (en) * | 1979-02-08 | 1982-03-23 | Merz & Co. | Certain substituted phenyl esters of nicotinic acid, compositions and methods of using same |
| DE3009099A1 (de) * | 1980-03-10 | 1981-09-17 | Merz + Co GmbH & Co, 6000 Frankfurt | Neue phenylester der nikotinsaeure und verfahren zu ihrer herstellung |
| GB2193359B (en) * | 1986-07-31 | 1990-07-11 | Multitone Electronics Plc | Area communications systems |
| US4797656A (en) * | 1987-01-28 | 1989-01-10 | Keppler Charles N | Appliance paging system |
| US5012749A (en) * | 1988-12-27 | 1991-05-07 | The Allen Group Inc. | Radio controlled material handling apparatus |
| US4962377A (en) * | 1989-02-09 | 1990-10-09 | Motorola, Inc. | Paging by text matching |
-
1983
- 1983-05-02 DE DE19833315877 patent/DE3315877A1/de active Granted
-
1984
- 1984-04-26 CH CH2092/84A patent/CH660005A5/de not_active IP Right Cessation
- 1984-04-26 YU YU74384A patent/YU45900B/sh unknown
- 1984-04-26 SE SE8402297A patent/SE454986B/sv not_active IP Right Cessation
- 1984-04-27 NL NL8401357A patent/NL8401357A/nl not_active Application Discontinuation
- 1984-04-28 HU HU841684A patent/HU191681B/hu not_active IP Right Cessation
- 1984-04-30 ES ES532079A patent/ES532079A0/es active Granted
- 1984-04-30 KR KR1019840002323A patent/KR860001907B1/ko not_active IP Right Cessation
- 1984-04-30 GR GR74551A patent/GR79862B/el unknown
- 1984-05-01 DK DK216484A patent/DK159105C/da not_active IP Right Cessation
- 1984-05-01 GB GB08411081A patent/GB2139621B/en not_active Expired
- 1984-05-01 IE IE1074/84A patent/IE57393B1/en not_active IP Right Cessation
- 1984-05-01 CA CA000453248A patent/CA1247092A/en not_active Expired
- 1984-05-02 IL IL71734A patent/IL71734A/xx unknown
- 1984-05-02 BE BE0/212858A patent/BE899558A/fr not_active IP Right Cessation
- 1984-05-02 CS CS843252A patent/CS241082B2/cs unknown
- 1984-05-02 FR FR8406845A patent/FR2545486B1/fr not_active Expired
- 1984-05-02 AU AU27604/84A patent/AU564780B2/en not_active Ceased
- 1984-05-02 FI FI841736A patent/FI80444C/fi not_active IP Right Cessation
- 1984-05-02 JP JP59087963A patent/JPS59206357A/ja active Granted
- 1984-05-02 IT IT8420763A patent/IT1206144B/it active
- 1984-05-02 ZA ZA843278A patent/ZA843278B/xx unknown
- 1984-05-02 LU LU85344A patent/LU85344A1/fr unknown
-
1987
- 1987-09-29 US US07/102,025 patent/US4758581A/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0551230B1 (de) | Cyano-2-Hydroxy-3-Enamid-Derivate, Verfahren zu ihrer Herstellung, ihre Verwendung als Arzneimittel, diese enthaltende pharmazeutische Zusammensetzungen und erhaltene Zwischenprodukte | |
| FR2535321A1 (fr) | Nouveaux derives de l'ethanol, leur preparation et leur utilisation comme fongicides | |
| LU82087A1 (fr) | N-benzylimidazoles inhibiteurs selectifs de thromboxannesynthetase,leur procede de production et compositions pharmaceutiques les contenant | |
| FR2501686A1 (fr) | Nouveaux derives de 3,4-dihydro-5h-2,3-benzodiazepine, procede pour les preparer et medicaments les contenant | |
| LU79824A1 (fr) | Nouveaux hexahydro-1-hydroxy-9-hydroxymethyl-6h-dibenzo-(b,d)pyranes substitues en position 3,leur procede de preparation et composition pharmaceutique les contenant | |
| EP0041021A2 (de) | Cyclopropancarbonsäure-Derivate, ihre Herstellung, ihre Verwendung gegen Parasiten von Pflanzen und Tieren, ihre Zusammensetzungen und ihre Zwischenprodukte | |
| FR2491467A1 (fr) | Nouveaux n-alkyl inferieur)-3-phenoxy-1-azetidinecarboxamides possedant notamment une activite sur le systeme nerveux central, et leur procede de preparation | |
| EP0646578B1 (de) | Phenyl-Carboxamide-Isoxazole-Derivate und Salze, Verfahren zu ihrer Herstellung ihre Anwendung als Arzneimittel und pharmazeutische Zusammensetzungen die sie enthalten | |
| EP0556123A1 (de) | Pyrethroidester von Thiazolylalkoholen, Verfahren zu ihrer Herstellung und ihre Verwendung als Pestizide | |
| LU85344A1 (fr) | N-oxydes d'esters d'acide pyridyl carboxylique,leur preparation et leur utilisation | |
| LU81598A1 (fr) | Nouveaux derives d'imidazole,leur procede de production et composition pharmaceutique les contenant | |
| EP0117771A1 (de) | Imino-2-pyrrolidine, Verfahren zu ihrer Herstellung und ihre therapeutische Verwendung | |
| EP0606175B1 (de) | 2-Cyano-2-hydroxypropenamidederivate, Verfahren zu ihrer Herstellung ihre Verwendung als Arzneimittel und diese enthaltende pharmazeutische Zusammensetzungen | |
| FR2463141A1 (fr) | Nouveaux derives de 10-halo-e-homoeburnane, procede de preparation de ces nouveaux derives et medicaments les contenant | |
| BE830534A (fr) | O-acyl-acrylaldoximes substituees, leur preparation et leurs applications | |
| FR2706898A1 (de) | ||
| EP0168309B1 (de) | Isoxazolochinolinonderivate, Verfahren und Zwischenprodukte zu ihrer Herstellung, Verwendung als Arzneimittel und die sie enthaltenden Zubereitungen | |
| CA2062407A1 (fr) | Derives du benzopyrane leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| FR2650592A1 (de) | ||
| LU85348A1 (fr) | Nouveaux derives d'acylaminophenols,leur preparation et leur utilisation comme medicaments | |
| BE882140R (fr) | Derives aromatiques, leur procede de preparation et leur utilisation | |
| CH624379A5 (en) | Process for the preparation of new 2-hydroxymethyl-2-phenyl-1,3-indanedione esters | |
| WO2012104538A1 (fr) | Nouveaux dérivés de 1, 5 - dihydropyrrol - 2 - one utiles pour le traitement paludisme ou d'autres maladies parasitaires et fongiques | |
| BE862019R (fr) | Nouveaux derives de la vincamine, leur preparation et leur application comme medicaments | |
| BE887671A (fr) | Preparations pharmaceutiques topiques contenant des sels d'acides alcane-carboxyliques ainsi que de nouveaux sels d'acides carboxyliques et leurs procedes de preparation |